Chilton Capital Management LLC Purchases 235,131 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Chilton Capital Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 125,738.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 235,318 shares of the biopharmaceutical company's stock after purchasing an additional 235,131 shares during the period. Chilton Capital Management LLC's holdings in Gilead Sciences were worth $26,367,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in Gilead Sciences by 20.6% in the 4th quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company's stock valued at $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Proficio Capital Partners LLC acquired a new stake in shares of Gilead Sciences in the fourth quarter worth $339,000. Ashton Thomas Private Wealth LLC boosted its position in shares of Gilead Sciences by 2.2% in the fourth quarter. Ashton Thomas Private Wealth LLC now owns 44,217 shares of the biopharmaceutical company's stock worth $4,084,000 after buying an additional 932 shares during the period. Destination Wealth Management acquired a new position in shares of Gilead Sciences during the fourth quarter worth $362,000. Finally, Machina Capital S.A.S. increased its position in shares of Gilead Sciences by 13.6% during the fourth quarter. Machina Capital S.A.S. now owns 17,310 shares of the biopharmaceutical company's stock worth $1,599,000 after acquiring an additional 2,071 shares during the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total value of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares in the company, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction on Monday, June 16th. The stock was sold at an average price of $110.17, for a total transaction of $275,425.00. Following the transaction, the chief financial officer directly owned 165,110 shares of the company's stock, valued at approximately $18,190,168.70. This represents a 1.49% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 58,500 shares of company stock worth $6,340,745. 0.27% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research analysts have commented on the company. JPMorgan Chase & Co. increased their target price on Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a report on Thursday, March 27th. Morgan Stanley upped their price target on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Cantor Fitzgerald initiated coverage on shares of Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Oppenheimer dropped their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Nine research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $110.55.

Gilead Sciences Stock Down 0.4%

NASDAQ GILD traded down $0.42 on Monday, reaching $111.33. The stock had a trading volume of 1,429,945 shares, compared to its average volume of 7,681,420. The company has a current ratio of 1.37, a quick ratio of 1.23 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 1 year low of $66.34 and a 1 year high of $119.96. The business has a 50 day moving average price of $107.02 and a 200 day moving average price of $104.11. The company has a market capitalization of $138.48 billion, a price-to-earnings ratio of 23.44, a P/E/G ratio of 0.72 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, topping analysts' consensus estimates of $1.77 by $0.04. The firm had revenue of $6.67 billion for the quarter, compared to the consensus estimate of $6.77 billion. Gilead Sciences had a return on equity of 51.93% and a net margin of 20.76%. The firm's revenue was down .3% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.32) earnings per share. On average, analysts forecast that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date was Friday, June 13th. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.84%. Gilead Sciences's dividend payout ratio is currently 66.53%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.